anethole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arumugam, P; Balusamy, SR; Perumalsamy, H; Ramesh, V; Sampathkumar, B; Sundaravadevel, S | 1 |
| Arumugam, P; Balraj, S; Balusamy, SR; Nachimuthu, SK; Perumalsamy, H; Ramesh, V; Sampathkumar, B; Suganya, K; Sundaravadivelu, S | 1 |
1 review(s) available for anethole and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Integrative transcriptome analysis of triple negative breast cancer profiles for identification of druggable targets.
Topics: Cell Line, Tumor; Doxorubicin; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Neoplasm Proteins; Protein Serine-Threonine Kinases; Transcriptome; Triple Negative Breast Neoplasms | 2023 |
1 other study(ies) available for anethole and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Synergistic effect of anethole and doxorubicin alleviates cell proliferation, cell cycle arrest, and ER stress and promotes ROS-mediated apoptosis in triple-negative breast cancer cells.
Topics: Allylbenzene Derivatives; Anisoles; Antibiotics, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Endoplasmic Reticulum Stress; Female; Humans; Reactive Oxygen Species; Triple Negative Breast Neoplasms | 2021 |